Studies on the hepatomegaly caused by the hypolipidemic drugs nafenopin and clofibrate
- 30 September 1972
- journal article
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 23 (1) , 42-53
- https://doi.org/10.1016/0041-008x(72)90202-5
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Effects of su‐13437, a new hypolipidemic drug, upon synthesis in vivo of hepatic and carcass total fatty acids and total cholesterolLipids, 1971
- Comparative clinical therapeutic trial with two hypolipidemic drugs: Clofibrate and nafenopinClinical Pharmacology & Therapeutics, 1971
- Lipid effects of a phenolic ether (Su-13437) in the rat: Comparison with CPIBAtherosclerosis, 1970
- Metabolism of SU‐13437‐a new hypolipidemic drug in manClinical Pharmacology & Therapeutics, 1970
- Hypolipidaemic properties of a new tetralin derivative (CIBA 13,437-Su)Cellular and Molecular Life Sciences, 1968
- Drug interactions with warfarinArchives of internal medicine (1960), 1968
- The metabolism of drugs by hepatic microsomal enzymes. Studies on intramicrosomal distribution of enzymes and relationships between enzyme activity and structure of the hepatic endoplasmic reticulumExperimental and Molecular Pathology, 1966
- NATURE OF THE HEPATOMEGALIC EFFECT PRODUCED BY ETHYL-CHLOROPHENOXY-ISOBUTYRATE IN THE RATNature, 1965
- Effects of α-p-chlorophenoxyisobutyryl ethyl ester (CPIB) with and without androsterone on cholesterol biosynthesis in rat liverJournal of Lipid Research, 1965
- The metabolism of drugs by subfractions of hepatic microsomesBiochemical and Biophysical Research Communications, 1961